CHMA - CHMA STOCK NEWS

Chiasma, Inc. (NASDAQ: CHMA) acknowledges Acromegaly Awareness Day on November 1, highlighting its dedication to patients and advocacy groups. The company will host a Facebook Live event titled “5 Tips to Achieve Effective Communications with Healthcare Teams,” featuring experts and patients. CEO Raj Kannan emphasized the firm’s commitment to acromegaly patients, reflecting on their innovative research that led to the FDA approval of MYCAPSSA, the first oral somatostatin analog for long-term treatment in the U.S. Chiasma aims to expand access to this therapy globally.

Chiasma (NASDAQ: CHMA) announced a conference call and webcast scheduled for November 5, 2020, at 5:00 PM ET. The event will cover the financial results for the quarter ending September 30, 2020, along with a business update. Investors can participate via domestic and international phone lines or through the company's webcast. An archived version will be available for one year post-event.

Chiasma, headquartered in Needham, MA, focuses on developing oral therapies for patients with chronic diseases.

Chiasma, Inc. has launched MYCAPSSA® (octreotide) capsules in the U.S. for acromegaly patients. Approved by the FDA on June 26, 2020, MYCAPSSA is the first oral somatostatin analog for long-term maintenance therapy in patients who have tolerated prior octreotide or lanreotide treatment. CEO Raj Kannan emphasized the significance of this launch in an injectable-dominated market, while CCO Anand Varadan highlighted the company’s trained sales team ready for rollout. Chiasma estimates about 8,000 adults in the U.S. are treated with somatostatin analog injections annually.

Chiasma, Inc. (NASDAQ: CHMA) is poised for the U.S. commercial launch of MYCAPSSA® in the fourth quarter after achieving FDA approval. The company reported a net loss of $21.1 million for Q2 2020, reflecting increased operational costs as it transitions to a commercial stage. Key financial updates include a strong cash position of $87.1 million and securing up to $75 million from financing agreements. Upcoming milestones include the anticipated MPOWERED Phase 3 trial topline data release, expected in the same quarter.

Chiasma, a biopharmaceutical company, will host a conference call on August 10, 2020, at 5:00 PM Eastern Time to discuss its financial results for the second quarter of 2020 and provide a business update. Investors can participate by calling 855-327-6837 in the U.S. or 631-891-4304 internationally, using conference ID 10010555. A live audio webcast will also be available, with an archived replay accessible on their website for one year. Chiasma recently received FDA approval for MYCAPSSA, the first oral somatostatin analog for acromegaly patients.

Chiasma, Inc. (NASDAQ: CHMA) announced positive results from the 48-week open-label extension of its Phase 3 CHIASMA OPTIMAL trial for MYCAPSSA (octreotide) capsules. The mean IGF-1 levels for treated patients remained within normal limits, with 93% of responders maintaining their response. The study, which examined long-term safety and efficacy, showed that 90% of patients completed the OLE period. MYCAPSSA is the first FDA-approved oral somatostatin analog, now indicated for long-term maintenance treatment in acromegaly patients.

Chiasma (NASDAQ: CHMA) has priced an underwritten public offering of 12,500,000 shares of its common stock at $4.00 per share and pre-funded warrants for up to 5,000,000 shares at $3.9999 each. The offering, expected to close by July 6, 2020, includes an option for underwriters to purchase an additional 2,625,000 shares. Chiasma anticipates gross proceeds of $70 million, aimed at advancing the commercialization of MYCAPSSA® for acromegaly, supporting regulatory submissions in Europe, and funding early clinical development of pipeline candidates.

Chiasma, Inc. (NASDAQ: CHMA) has launched an underwritten public offering of its common stock, which may include pre-funded warrants to purchase common stock. The company plans to use the net proceeds primarily for the commercialization of MYCAPSSA® for acromegaly in the U.S., regulatory submissions to the European Medicines Agency, early clinical development of pipeline candidates, and general corporate purposes. The offering is contingent on market conditions, with a potential 30-day option for underwriters to purchase an additional 15% of the shares.

Chiasma announced the FDA approval of MYCAPSSA (octreotide capsules) for long-term maintenance treatment in acromegaly patients. This marks MYCAPSSA as the first and only oral somatostatin analog approved, utilizing Chiasma's Transient Permeability Enhancer technology. The approval is based on positive results from the Phase 3 CHIASMA OPTIMAL trial, indicating effective maintenance of IGF-1 levels. The company plans to launch MYCAPSSA commercially in Q4 2020 and aims to support patients through a comprehensive service program.